Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL27770019 | 1.00 | LMNA (0.57) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Maleic Acid SCHEMBL27770020 | 1.00 | LMNA (0.57) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Fumaric Acid SCHEMBL27770022 | 1.00 | LMNA (0.57) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Cinnamic Acid SCHEMBL27791371 | 0.90 | NPC1 (0.69) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL4914089 | 0.88 | CES2 (0.67) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL61183 | 0.88 | — | — | |
| SCHEMBL1505348 | 0.88 | — | — | |
| Ammonia Solution, Strong SCHEMBL902138 | 0.86 | CES2 (0.64) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Hydrochloric Acid SCHEMBL17493405 | 0.86 | CES2 (0.64) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| Hydrochloric Acid SCHEMBL1704886 | 0.86 | CES2 (0.64) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101636388-B | 637 pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2013-09-18 | — | — | CN | claimed |
| CN-104147011-A | Uses of pyridine-diketone serving as PDE4 inhibitor for treating eye diseases | ASTRAZENECA AB | 2014-11-19 | — | — | CN | disclosed |
| CN-101636388-B | 637 pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2013-09-18 | — | — | CN | disclosed |
| CN-102532135-A | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| CN-101636388-A | Compound 637: pyridopyrimidinediones as PDE4 inhibitors | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | KMT2A 422/4885MEN1 869/4885LMNA 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.